Webinar-Looking to detect SNPs or other point mutations in samples that have a limited number of DNA copies?

Looking to detect SNPs or other point mutations in samples that have a limited number of DNA copies?

Join our in-house experts William Ferreira, Ph.D. and Steve Hawkins, Ph.D., for their latest webinar where they share their insights on the newest range of Lyo-Ready™ Genotyping Direct qPCR Master mixes that support commercial assays designed to detect mutations.

In this presentation, you will learn how to detect single nucleotide polymorphisms (SNPs) directly from blood, plasma, urine, stool or FFPE tissue (down to 1 copy/reaction) using a simplified workflow that eliminates the need for nucleic acid extraction.


William Ferreira, Ph.D., R&D Team Leader

Steve Hawkins, Ph.D., Product Marketing Manager

View Recording

webinar transforming cancer

Transforming Cancer Detection with Liquid Biopsy

Liquid biopsy is fast becoming the method of choice for cancer diagnosis in the field of precision medicine, allowing oncologists to choose a targeted therapy, monitor treatment resistance and detect minimal residual disease, without patients undergoing an invasive procedure. Liquid biopsy utilizes bodily fluids such as blood, stool, urine and saliva to detect cancer biomarkers earlier than conventional methods such as tissue biopsy. It is also useful to screen for drug-resistant subpopulations, micro-metastases, minimum residual disease and disease relapse. The non-invasive approach of liquid biopsies enables samples to be taken easily and repeatedly over the course of a patient’s treatment, overcoming the inherent shortcomings and risks of surgical tissue biopsies. This panel discussion will review how liquid biopsy is opening up new avenues in cancer detection and continuous monitoring for personalized cancer treatment, as well as the screening of cancer markers for therapeutic resistance. Four industrial leaders in the field of molecular diagnostics will come together to discuss the current status of liquid biopsy for cancer screening, as well as how modern technologies are changing the landscape of cancer detection and CDx.

Chris Sale (CEO, Nonacus, UK)
Shidong Jia, PhD (CEO, Predicine, USA)
Hongjun (Harry) Yang, PhD (Senior VP of CDx, DiaCarta, USA)
Florent Chang-Pi-Hin PhD (VP of R&D, Meridian Bioscience, USA)

Steve Hawkins, PhD (Product Marketing Manager, Meridian Bioscience)

View Recording

Webinar Liquid Biopsy Video  new

Highly sensitive qPCR detection of biomarkers from liquid biopsies

Liquid biopsy is a non-invasive alternative to tissue biopsy based on ultra-sensitive detection of tumor-derived material such as ctRNA and ctDNA from biofluids, including blood, urine, stool, saliva, and sputum. qPCR based liquid biopsy possesses several advantages in cost and throughput, when compared to other technologies like NGS and ddPCR. In this talk, we will discuss Meridian’s new advances in inhibitor tolerant qPCR based liquid biopsy, that reduces the cost and complexity of these assays, while enabling ultra-sensitive detection from very low concentration cancer markers.

Steve Hawkins
Ph.D. – Product Marketing Manager

Michele Amasio, Ph.D.
Research and Development Senior Manager

View Recording